WO2014182044A1 - 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물 - Google Patents
쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물 Download PDFInfo
- Publication number
- WO2014182044A1 WO2014182044A1 PCT/KR2014/004012 KR2014004012W WO2014182044A1 WO 2014182044 A1 WO2014182044 A1 WO 2014182044A1 KR 2014004012 W KR2014004012 W KR 2014004012W WO 2014182044 A1 WO2014182044 A1 WO 2014182044A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- menopausal
- disease
- fermented soybean
- Prior art date
Links
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 235000020712 soy bean extract Nutrition 0.000 title claims abstract description 63
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 230000009245 menopause Effects 0.000 title claims description 22
- 208000024891 symptom Diseases 0.000 title claims description 7
- 208000017657 Menopausal disease Diseases 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims description 47
- 235000010469 Glycine max Nutrition 0.000 claims description 43
- 244000068988 Glycine max Species 0.000 claims description 42
- 230000008569 process Effects 0.000 claims description 32
- 230000035784 germination Effects 0.000 claims description 31
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 24
- 238000000855 fermentation Methods 0.000 claims description 24
- 230000004151 fermentation Effects 0.000 claims description 24
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 23
- 244000005700 microbiome Species 0.000 claims description 18
- 230000006872 improvement Effects 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 12
- 230000037394 skin elasticity Effects 0.000 claims description 11
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 241000228245 Aspergillus niger Species 0.000 claims description 4
- 240000006439 Aspergillus oryzae Species 0.000 claims description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 230000037336 dry skin Effects 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 241000131386 Aspergillus sojae Species 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010040880 Skin irritation Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 230000036556 skin irritation Effects 0.000 claims description 2
- 231100000475 skin irritation Toxicity 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 28
- 238000000605 extraction Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000002609 medium Substances 0.000 description 16
- 210000001672 ovary Anatomy 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 230000002611 ovarian Effects 0.000 description 12
- 206010027304 Menopausal symptoms Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 108010050808 Procollagen Proteins 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000037182 bone density Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 241001107116 Castanospermum australe Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 235000021279 black bean Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 235000021384 green leafy vegetables Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 2
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 2
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000006089 Phaseolus angularis Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 240000007098 Vigna angularis Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HDMHBHNRWDNNCD-UHFFFAOYSA-N 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine Chemical compound OCCOCN1C(=O)NC(=O)C(C)=C1SC1=CC=CC=C1 HDMHBHNRWDNNCD-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000741967 Homo sapiens Presequence protease, mitochondrial Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000266501 Ormosia ormondii Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100038632 Presequence protease, mitochondrial Human genes 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000008301 Rhynchosia minima Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100027224 Tumor protein p53-inducible nuclear protein 1 Human genes 0.000 description 1
- 108050003317 Tumor protein p53-inducible nuclear protein 1 Proteins 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002096 Vicia faba var. equina Nutrition 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000037333 procollagen synthesis Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- VMSRVIHUFHQIAL-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate Chemical compound [Na+].CN(C)C([S-])=S VMSRVIHUFHQIAL-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Definitions
- the present invention relates to a composition for the prevention of menopausal diseases including a soybean extract containing cumestrol as an active ingredient, and more particularly, to the prevention of menopausal diseases including a germinated fermented soybean extract containing cumestrol. To a composition.
- Menopausal symptoms are diseases caused by decreased secretion of male and female hormones. In particular, in women, the disease occurs over 2 to 10 years before and after menopause due to decreased secretion of estrogens due to aging of the ovaries. Hyperthermia, sweat, insomnia, depression, incontinence, pain, osteoporosis, myocardial infarction, stroke, The same symptoms are caused.
- Osteoporosis the most representative disease of menopausal symptoms, refers to a condition in which total bone mass decreases due to an increase in osteoclast activity compared to osteoblasts.
- osteoporosis occurs, the width of the cortical bone is reduced, the cavity of the bone marrow is enlarged, the reticulum is lowered, and the bone continues to be porous.
- the bone's physical strength decreases, causing low back pain and joint pain, and the bone easily breaks down even with a slight impact.
- hormone replacement therapy For the prevention and treatment of these menopausal symptoms, hormone replacement therapy, nonsteroidal preparations and drug treatments for osteoporosis treatment and the like have been developed, and at present, hormone replacement therapy is used as the most effective method.
- hormone replacement therapy is used as the most effective method.
- disadvantages such as side effects such as carcinogenic risk, headache, and weight gain. Therefore, there is an urgent need for the development of therapeutic agents using safer and more effective natural derived materials.
- An object of the present invention to provide a composition comprising a natural extract that is effective for menopausal symptoms or diseases.
- the present invention provides a pharmaceutical composition for preventing or treating menopausal disease, comprising a germinated fermented soybean extract containing cumestrol as an active ingredient.
- the present invention also provides a health food composition for preventing or improving menopausal disease, comprising a germinated fermented soybean extract containing cumestrol as an active ingredient.
- the present invention provides a cosmetic composition for the prevention or improvement of menopausal skin symptoms comprising a germinated fermented soybean extract containing cumestrol as an active ingredient.
- the composition of the present invention can be usefully used for the prevention, treatment and improvement of menopausal disease or menopausal symptoms by including a germination fermentation extract containing cumestrol as an active ingredient.
- the composition of the present invention can alleviate the degree of weight gain due to menopause, restore bone density to a level similar to that before menopause, and reduce the skin thickness reduction and skin elasticity reduction due to menopause.
- the composition of the present invention can also alleviate the skin moisture loss level according to menopause, can activate estrogen, reduce the amount of MMP1 that breaks down collagen and increase the amount of procollagen, thus menopausal disease It can also be useful for menopausal symptoms.
- the composition of the present invention has the advantage that there is no resistance and long-term side effects even when used for a long time using a natural product as an active ingredient.
- 1 is a graph measuring weight change of 14 weeks in the menopausal induced mouse model through ovarian extraction (x-axis: week, y-axis: gram (g)).
- Figure 2 is a result of measuring the skin thickness of 30-week-old hairless mice in the menopausal induced mouse model through ovarian extraction (y-axis: gram (g)).
- Figure 3 shows the results of measuring the skin elasticity and viscosity of hairless mice in the menopausal induced mouse model through ovarian extraction (y-axis: unit).
- Figure 4 shows the results of measuring the moisture evaporation of the skin of the hairless mouse in the menopausal induced mouse model through ovarian extraction.
- Figure 6 compares the extent to which each experimental group inhibits the expression of MMP1.
- Figure 7 compares the degree of procollagen synthesis amount by each experimental group.
- the present invention relates to a pharmaceutical composition for preventing or treating menopausal diseases, comprising, as an active ingredient, a germinating fermented soybean extract containing cumestrol as an active ingredient in one aspect.
- the present invention relates to a health food composition for preventing or improving menopausal diseases, including a germinated fermented soybean extract containing cumestrol as an active ingredient.
- the present invention relates to a cosmetic composition for preventing or ameliorating menopausal skin symptoms, comprising a germinated fermented soybean extract containing cumestrol as an active ingredient.
- the “bean” may be used without limitation as long as it can germinate and include legumes to include or synthesize cumestrol.
- the beans may be varieties for beans and tofu, herbs, rice or foot beans.
- the beans may be varieties for beans and tofu, herbs, rice or foot beans.
- jang and tofu varieties Dafeng, Hojang, and Jangwon ), Rhubarb, Sodam, Songhak, Daewon, Genuine, Protein, Soymilk, Shinpaldal, Taekwang ), Great Wall, Longevity ( ), Wuhan, Baiyun, Egg, Golden ( Varieties for herbs, such as Xinhua, beacon, Anping, southwest, colorful, Solok, Soho, Calligraphy, tea garden, Pungshan greens, Iksan greens, Sobaek greens, Gwangan, single leaves and galaxies.
- varieties for green soybeans include Daol, fresh green, birds,
- the "bean” is Seoritae (Glycin max MERR), Seomoktae (Seomoktae, Rhynchosia Nolubilis ), Black soybean ( Glycine max (L.) Merr.), Blue bean ( Glycine) max MERR, yellow bean, Glycine max MERR, field bean, Vicia faba , kidney bean, Phaseolus vulgaris , pinto bean, Phaseolus vulgaris L., small red bean , Vigna angularis ), small black bean, Phaseolus angularis .F.WIGHT., Bean sprouts (sprouting bean, Glycine max (L.) Merr.) And soybeans (soybean, Glycine max ) It may be abnormal.
- the “germinated fermented soybean” refers to a soybean germination process and a fermentation process performed simultaneously or sequentially.
- the conditions of at least one of the germination process and the fermentation process is not particularly limited as long as the germination and fermentation conditions can be made continuously.
- Examples of germination or fermentation process conditions are as follows.
- the germination process may proceed by contacting at least a portion of the beans with oxygen or air.
- the germination process can be carried out in a reactor, the germination process can be carried out in a reactor comprising 20 to 80% by volume, specifically 40 to 60% by volume, more specifically 45 to 55% by volume relative to the reactor volume. have.
- the medium to be used in the germination process is not particularly limited as long as the medium can be smoothly germinated and / or fermentation, specifically, a liquid nutrition medium, more specifically, PDB medium (potato dextrose broth) is an example.
- the medium may comprise 0.001 to 10% by weight, specifically 0.1 to 5% by weight, more specifically 0.5 to 2% by weight, based on the total weight of the medium.
- the germination process may be carried out by inoculating 1 to 50% by volume, specifically 5 to 20% by volume, more specifically 6 to 12% by volume of beans in the reactor.
- the germination process may proceed with the maximum supply of oxygen or air.
- oxygen or air may be supplied at 15,000vvm / m.
- the germination process may be carried out at a temperature of 20 to 35 °C, specifically 20 to 30 °C. In another aspect of the present invention, the process may be performed under light shielding conditions. In another aspect of the invention, the process may be performed for 2 to 10 days. For example, after the germination process is performed for 2 days, the germination process and the fermentation process may be performed at the same time or at a time difference for 6 to 8 days.
- the fermentation process may proceed by contacting at least a portion of the beans with the microorganism.
- the fermentation process may be carried out by inoculating microorganisms in beans 1 to 10 times, specifically 1 to 5 times, more specifically 1 to 3 times.
- This process allows microorganisms to better contact soybeans.
- the microorganism may be applied without limitation as long as the microorganism that enables the fermentation of soy known in the art, specifically may be fungi, yeast or lactic acid bacteria.
- the fungus may be a microorganism of the genus Aspergillus , Penicillium or Monascus, and the microorganism may be Aspergillus niger or Aspergillus. sojae ), Aspergillus oryzae and Bifidobacterium infantis .
- the fermentation process may be applied without limitation as long as it is in a form capable of contact with microorganisms and beans.
- the suspension solution of the microorganism spores may be contacted with soybeans by applying the suspension solution of the soybean cotyledon or by adding microbial powder to the medium containing the soybeans.
- 0.05 to 2% by weight, specifically 0.75 to 2% by weight, more specifically 1.0 to 2.0% by weight of microorganisms may be contacted with soybean, based on the weight of the medium.
- the germination process and fermentation process in the production of the "germinated fermented soybeans” may be proceeded by a method of contacting with oxygen or air in contact with the microorganisms.
- the soybean may be in contact with the oxygen or air in the state immersed in the medium containing the microorganism.
- the germination process and the fermentation process may be obtained sequentially, for example, after the germination process, the fermentation process, or after the fermentation process. Specifically, after the germination process is carried out for 2 days, the germination process and the fermentation process may be carried out simultaneously or sequentially to proceed for 6 to 8 days.
- the soybeans may further include a sterilization process of washing with one or more of sterilized water, ethanol and sodium hypochlorite, specifically, sterilized water.
- soybean containing cumestrol obtained through the process as described above the extract obtained by cooling or warming at room temperature with water or ethanol is completely concentrated, and then dispersed in water, and the same amount of hexane and dichloromethane.
- Soybean extracts containing cumestrol can be obtained by fractionation with one or more solvents selected from chloroform, ethyl acetate, butanol, ethanol, methanol and water.
- the extraction method is not limited thereto, and any extraction method may be used such that the final extract contains cumestrol.
- the "cumestrol” may have a structure such as the following Chemical Formula 1.
- the menopausal disease may include muscle disease caused by menopause, bone disease, heart disease, skin disease or obesity.
- the muscle disease is rheumatoid arthritis or degenerative arthritis due to menopause;
- the bone disease is menopausal osteoporosis, back pain, rickets, osteomalacia or Paget's diseas of bone;
- the heart disease is menopausal angina or arteriosclerosis;
- the skin disease may be skin redness or dry skin.
- the skin symptoms caused by menopause may include, but are not limited to, skin redness, obesity, skin thickness change, skin elasticity reduction, or dry skin, but is not limited thereto. It is all inclusive.
- the pharmaceutical composition according to one embodiment of the present invention may further contain a pharmaceutical adjuvant and other therapeutically useful substances such as preservatives, stabilizers, hydrating or emulsifiers, salts and / or buffers for controlling osmotic pressure, It may be formulated in various oral or parenteral dosage forms according to conventional methods.
- the oral dosage forms include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to active ingredients.
- Diluents e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine
- glidants e.g. silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols
- Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium It may contain pharmaceutical additives such as disintegrants such as salts, absorbents, colorants, flavors, and sweeteners.
- binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium
- disintegrants such as salts, absorbents, colorants, flavors, and sweeteners.
- the tablets can be prepared by conventional mixing, granulating or coating methods.
- parenteral administration agent may be, for example, formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, patches, and the like. It is not.
- compositions according to an embodiment of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
- Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
- the pharmaceutically acceptable dose, ie dosage, of the active ingredient depends on the age, sex and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Will depend. Dosage determination based on these factors is within the level of skill in the art. Typical dosages may be from 0.01 mg / kg / day to 1000 mg / kg / day and from 1 mg / kg / day to 40 mg / kg / day, but the dosage may in any way be within the scope of the present invention. It is not limitative.
- the health food composition according to another embodiment of the present invention can be processed into fermented milk, cheese, yogurt, juice, probiotic and health supplements, etc., it can be used in the form of various other food additives.
- the said composition may contain the other component etc. which can give a synergistic effect to a main effect in the range which does not impair the main effect aimed at by this invention.
- it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials for improving the physical properties.
- additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials for improving the physical properties.
- auxiliary ingredients such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract.
- the components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention.
- compositions according to the invention may be in various forms, such as solutions, emulsions, viscous mixtures, tablets, powders, and the like, which may be administered by various methods such as simple drinking, injection, spray or squeeze.
- the soybean may be a germinated fermented soybean germination process and fermentation process proceeded simultaneously or sequentially.
- the soybean may be a fermentation process after the germination process.
- the germination process may be performed in a reactor containing 20 to 80% by volume of the total volume of the reactor, 1 to 50% by volume of the beans relative to the total volume of the reactor.
- the germination process may be performed for 2 to 10 days at a temperature of 20 to 35 °C and dark conditions.
- the fermentation process may be to contact the germinated soybean and the microorganism.
- the microorganism may be one or more selected from the group consisting of fungi, yeast and lactic acid bacteria.
- the microorganism is Aspergillus niger ( Aspergillus niger ), Aspergillus sojae ( Aspergillus sojae ), Aspergillus oryzae and Bifidobacterium Infantis ( Bifidobacterium) infantis ) may be one or more selected from the group consisting of.
- the composition may comprise a germinated fermented soybean extract containing cumestrol in 0.0001 to 10% by weight relative to the total weight of the composition.
- the extract When the extract is contained at less than 0.0001% by weight, the effect on menopausal symptoms or diseases is somewhat insignificant, and when contained in excess of 10% by weight, it affects the range of other components of the composition.
- the composition may comprise 0.001 to 9.5% by weight, 0.01 to 9% by weight or 0.1 to 8.5% by weight of cumestrol relative to the total weight of the composition.
- Beans were used Pungsan herb beans (Wish beans, Glycine max (L.) Merrill). Seeds of soybeans were washed and sterilized twice with sterile water, ethanol and sodium hypochlorite. Thereafter, a medium comprising one or more of 1% sucrose, 1% glucose and 1% SRT was prepared in an amount of 20 to 80% by volume relative to the reactor volume. For example, when using a reactor of 10 tons, the amount of medium was 8 tons. In addition, the seeds of the beans were inoculated at a density of 3 to 12% by volume relative to the reactor volume. For example, when using a reactor of 10 tons, the amount of seeds used was 1.2 tons. Seeds of soybeans were germinated under conditions of temperature 25 ° C., shading and air supply 15000vvm / m in a reactor containing medium and soybean seeds.
- the extract obtained by adding hot water of 80 ° C. or more to the germinated fermented soybean thus obtained was used after drying.
- the concentration of cumestrol in the germinated fermented soybean extract was about 0.1%.
- mice female hairless mice weighing 26 to 27 g were used.
- the experimental animals were bred under conditions of temperature 23 ⁇ 1 ° C., humidity 40 to 60%, and contrast cycle 12 hours, and basic feed and drinking water were supplied without limitation. However, on the day before blood collection, only drinking water was supplied.
- Ovariectomy was performed by anesthetizing 15-week-old hairless mice, sterilizing with 70% ethanol and aseptically.
- the skin tissue was incised about 2 to 3 cm along the lower vertebral line of one side abdomen, and then 1.5 cm of the muscle and peritoneum where the ovary was located was exposed to expose the ovary.
- the ovaries were excised and silk was used to suture the peritoneum, muscles and skin.
- the ovary was also extracted on the other side in the same way.
- As a control group the same procedure was performed only to the peritoneum, and the sham operation was performed again without suturing the ovary.
- the recovery period was one week after surgery.
- the experimental animals were divided into the control group (the most surgical group) and the ovary extraction group, and the ovary extraction group was divided into 10 groups each of 500 mg / kg administration of germinated fermented soybean extract and 0.5 mg / kg administration of cumestrol.
- feed was prepared at the same dosage as above, and the intake period was 14 weeks until 30 weeks of age using 16-week-old mice one week after ovarian ablation.
- weight gain is more common than normal group. This is a common phenomenon among menopausal women, and it is obvious to those skilled in the art that if there is an effect of improving weight gain in the ovarian extraction model, it can be expected to have great effects on menopausal obesity.
- Table 1 shows the results of bone density measurement using the dual energy radiation bone density meter for the same experimental group (30 weeks old) as the experimental group used in Experimental Example 1.
- Skin thickness was measured using a caliper (HEPT, Cjina) for the same experimental group (30 weeks old) as the experimental group used in Experimental Example 1.
- HEPT HEPT, Cjina
- the ovary extraction group was reduced by about 10% skin thickness compared to the control group without ovarian extraction, but the germinated fermented soybean administration group was confirmed to maintain the skin thickness almost similar to the control group there was.
- the group ingesting the same amount of cumestrol was found to show the same pattern as the ovary extraction group, so that the intake of germinated fermented soybean extract was found to have an excellent effect on improving skin thickness reduction according to menopause.
- a reporter assay was performed on the estrogen receptor.
- Indigo Bioscience's human ER reporter assay kit was treated with 100 ppm of germinated soybean extract (containing 0.1% cumestrol) and 0.1 ppm of cumestrol for 24 hours. 0.1 ppm of 17-estradiol was used.
- Estradiol acts as a ligand of the estrogen receptor, in particular to Estrogen Receptor ⁇ (ER ⁇ ) and Estrogen Receptor ⁇ (ER ⁇ ).
- ER ⁇ Estrogen Receptor ⁇
- ER ⁇ Estrogen Receptor ⁇
- luciferase activity was measured using a Tecan Infinite M200pro multiplate reader + injector system, and the results are shown in FIG. 5.
- the group to which the germinated fermented soybean extract was administered had a better binding effect on the estrogen receptor than the estradiol ligand of the estrogen receptor. Accordingly, the germinated fermented soybean extract would be able to generate the same signal as estrogen, so it could be expected to have a remarkable effect on menopausal disease or menopausal symptoms. In addition, this result was to activate the estrogen receptor to a superior degree than the group ingested the same amount of cumestrol, which seems to be a synergistic effect by the combination of various components in the germinated fermented soybean extract.
- MMP1 matrix metalloprotease 1
- iNOS oxidative stress inducing protein
- MMP1 collagenase
- menopausal skin is known to be weak against skin irritation such as ultraviolet rays because it is thinner.
- skin irritation such as ultraviolet rays
- a mattress was prepared by mixing 2.64 ⁇ 10 5 fibroblasts with collagen solution, and seeding 5 ⁇ 10 6 keratinocytes thereon to induce differentiation of artificial skin by inducing differentiation while treating 1.2 mM calcium. After induction of differentiation for 2 weeks, each of the cells were irradiated with 20mJ of UV light, treated with 0.1 ppm of cumestrol and 100 ppm of germinated fermented soybean extract, and then the medium was collected and MMP- in the same manner as in Experimental Example 5. 1 expression level and procollagen expression level were measured. When the group not irradiated with UV is set to 100, the relative values thereof are shown in Table 2.
- UV non-irradiation group 100.0% 100.0% UV irradiation group 142.4% 68.7% UV irradiation + cumestrol 122.8% 82.4% UV irradiation + germinated fermented soybean extract 108.3% 95.7%
- Fermented soybean extract 80 mg, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, lead beetle 4 mg, and lecithin 9 mg were mixed and mixed according to a conventional method. .
- 400 mg per capsule was filled to prepare a soft capsule.
- a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
- Germinated fermented soybean extract containing cumestrol, vitamin E 9mg, vitamin C 9mg, galactooligosaccharide 200mg, lactose 60mg and maltose 140mg are mixed and granulated using a fluidized bed dryer and then sugar ester 6 mg was added. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.
- the germinated fermented soybean extract containing Kumestrol 80mg, vitamin E 9mg, vitamin C 9mg, glucose 10g, citric acid 0.6g, and 25g of liquid oligosaccharides were mixed and 300ml of purified water was added to each bottle to 200ml. After filling the bottle sterilized for 4 to 5 seconds at 130 °C to prepare a beverage.
- Germinated fermented soybean extract including Kumestro, 80 mg of vitamin E, 9 mg of vitamin C, 250 mg of anhydrous glucose, and 550 mg of starch were mixed, molded into granules using a fluid bed granulator, and then filled into sachets.
- Table 8 Compounding ingredient Content (% by weight) Germinated Fermented Soybean Extract Containing Cumestrol 0.0025 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / Capric Triglycerides 3.0 Squalane 1.0 Cetearyl Glucoside 1.5 Sorbitan stearate 0.4 Cetearyl Alcohol 1.0 Beeswax 4.0 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- the present invention relates to a composition for the prevention of menopausal diseases including a soybean extract containing cumestrol as an active ingredient, and more particularly, to the prevention of menopausal diseases including a germinated fermented soybean extract containing cumestrol.
- a composition can be usefully used for the prevention, treatment and improvement of menopausal disease or menopausal symptoms by including a germination fermentation extract containing cumestrol as an active ingredient.
- the composition of the present invention can alleviate the degree of weight gain due to menopause, restore bone density to a level similar to that before menopause, and reduce the skin thickness reduction and skin elasticity reduction due to menopause.
- composition of the present invention can also alleviate the skin moisture loss level according to menopause, can activate estrogen, reduce the amount of MMP1 that breaks down collagen and increase the amount of procollagen, thus menopausal disease It can also be useful for menopausal symptoms.
- composition of the present invention has the advantage that there is no resistance and long-term side effects even when used for a long time using a natural product as an active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
구분 | 골밀도 (g/cm2) |
대조군 | 0.1975 |
난소 적출군 | 0.1821 |
난소 적출+쿠메스트롤 투여군 | 0.1902 |
난소 적출+발아발효콩 추출물 투여군 | 0.1959 |
MMP-1 | 프로콜라겐 | |
자외선 비조사군 | 100.0% | 100.0% |
자외선 조사군 | 142.4% | 68.7% |
자외선 조사 + 쿠메스트롤 | 122.8% | 82.4% |
자외선 조사 + 발아발효콩 추출물 | 108.3% | 95.7% |
배합 성분 | 함량 (중량 %) |
쿠메스트롤을 포함하는 발아발효콩 추출물 | 0.0025 |
글리세린 | 3.0 |
부틸렌글리콜 | 2.0 |
프로필렌글리콜 | 2.0 |
카르복시비닐폴리머 | 0.1 |
피이지-12 노닐페닐에테르 | 0.2 |
폴리솔베이트 80 | 0.4 |
에탄올 | 10.0 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량 (중량 %) |
쿠메스트롤을 포함하는 발아발효콩 추출물 | 0.0025 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
카르복시비닐폴리머 | 0.1 |
밀납 | 4.0 |
폴리솔베이트 60 | 1.5 |
카프릴릭/카프릭 트리글리세라이드 | 5.0 |
스쿠알란 | 5.0 |
솔비타세스퀴올레이트 | 1.5 |
유동파라핀 | 0.5 |
세테아릴 알코올 | 1.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
쿠메스트롤을 포함하는 발아발효콩 추출물 | 0.0025 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
유동파라핀 | 7.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
스쿠알란 | 5.0 |
세테아릴 글루코사이드 | 1.5 |
소르비탄 스테아레이트 | 0.4 |
폴리솔베이트 60 | 1.2 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
쿠메스트롤을 포함하는 발아발효콩 추출물 | 0.0025 |
글리세린 | 8.0 |
부틸렌글리콜 | 4.0 |
유동파라핀 | 45.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
밀납 | 4.0 |
세테아릴 글루코사이드 | 1.5 |
세스퀴 올레인산 소르비탄 | 0.9 |
바세린 | 3.0 |
파라핀 | 1.5 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
쿠메스트롤을 포함하는 발아발효콩 추출물 | 0.0025 |
글리세린 | 4.0 |
폴리비닐알콜 | 15.0 |
히알루론산 추출물 | 5.0 |
베타글루칸 | 7.0 |
알란토인 | 0.1 |
노닐 페닐에테르 | 0.4 |
폴리솔베이트 60 | 1.2 |
에탄올 방부제 | 6.0적량 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
쿠메스트롤을 포함하는 발아발효콩 추출물 | 0.0025 |
글리세린 | 8.0 |
부틸렌글리콜 | 4.0 |
유동파라핀 | 15.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
스쿠알란 | 1.0 |
세테아릴 글루코사이드 | 1.5 |
소르비탄 스테아레이트 | 0.4 |
세테아릴 알코올 | 1.0 |
밀납 | 4.0 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
Claims (14)
- 쿠메스트롤을 포함하는 발아발효콩 추출물을 유효성분으로 포함하는, 갱년기 질환의 예방 또는 치료용 약학 조성물.
- 쿠메스트롤을 포함하는 발아발효콩 추출물을 유효성분으로 포함하는, 갱년기 질환의 예방 또는 개선용 건강식품 조성물.
- 쿠메스트롤을 포함하는 발아발효콩 추출물을 유효성분으로 포함하는, 갱년기 피부 증상의 예방 또는 개선용 화장료 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서,상기 발아발효콩은 발아 공정과 발효 공정이 동시에 또는 순차적으로 진행된 콩인, 조성물.
- 제4항에 있어서,상기 콩은 발아 공정 후 발효 공정이 진행된 것인, 조성물.
- 제4항에 있어서,상기 발아 공정은 반응기 전체 부피 대비 20 내지 80 부피%의 배지를 포함하는 반응기 내에서, 반응기 전체 부피 대비 1 내지 50 부피%의 콩으로 진행되는 것인, 조성물.
- 제4항에 있어서,상기 발아 공정은 20 내지 35℃의 온도 및 암(巖) 조건에서 2 내지 10일간 진행되는 것인, 조성물.
- 제4항에 있어서,상기 발효 공정은 상기 발아 콩과 미생물을 접촉시키는 것인, 조성물.
- 제8항에 있어서,상기 미생물은 진균, 효모 및 유산균으로 구성된 군에서 선택되는 하나 이상인, 조성물.
- 제8항에 있어서,상기 미생물은 아스퍼질러스 니거(Aspergillus niger), 아스퍼질러스 소재(Aspergillus sojae), 아스퍼질러스 오리자에(Aspergillus oryzae) 및 비피도박테리움 인판티스(Bifidobacterium infantis)로 이루어진 군에서 선택된 하나 이상인, 조성물.
- 제1항 또는 제2항에 있어서,상기 갱년기 질환은 갱년기에 의한 근육질환, 골 질환, 심장 질환, 피부 질환 또는 비만인, 조성물.
- 제11항에 있어서,상기 근육질환은 갱년기에 의한 류마티스성 관절염 또는 퇴행성 관절염이거나;상기 골 질환은 갱년기에 의한 골다공증, 요통, 구루병, 골 연화증 또는 파제트 골 질환(Paget's diseas e of bone)이거나;상기 심장 질환은 갱년기에 의한 협심증 또는 동맥경화증이거나;또는상기 피부 질환은 피부 홍조 또는 피부 건조증인, 조성물.
- 제3항에 있어서,상기 갱년기 피부 증상은 피부 홍조, 피부 두께 감소, 피부 탄력 감소, 자외선에 의한 피부 자극 또는 피부 건조증인, 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서,상기 조성물은 조성물 총중량에 대하여 0.0001 내지 10중량%으로 쿠메스트롤을 포함하는 발아발효 콩 추출물을 포함하는, 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480031291.9A CN105473137B (zh) | 2013-05-06 | 2014-05-07 | 用于预防或治疗更年期症状的、包含作为活性成分的含有香豆雌酚的大豆提取物的组合物 |
EP14794096.9A EP2995304B1 (en) | 2013-05-06 | 2014-05-07 | Germinated and fermented bean extract and cosmetic or food use of a germinated and fermented bean extract |
US14/888,623 US10111856B2 (en) | 2013-05-06 | 2014-05-07 | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
JP2016512830A JP2016526019A (ja) | 2013-05-06 | 2014-05-07 | クメストロールを含む大豆抽出物を有効成分として含む更年期症状の予防および治療用組成物 |
HK16105025.0A HK1217285A1 (zh) | 2013-05-06 | 2016-05-03 | 用於預防或治療絕經期症狀的、包含作為活性成分的含有香豆雌酚的大豆提取物的組合物 |
US15/989,544 US10959981B2 (en) | 2013-05-06 | 2018-05-25 | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130050771 | 2013-05-06 | ||
KR10-2013-0050771 | 2013-05-06 | ||
KR10-2014-0053471 | 2014-05-02 | ||
KR1020140053471A KR102200014B1 (ko) | 2013-05-06 | 2014-05-02 | 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/888,623 A-371-Of-International US10111856B2 (en) | 2013-05-06 | 2014-05-07 | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
US15/989,544 Division US10959981B2 (en) | 2013-05-06 | 2018-05-25 | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014182044A1 true WO2014182044A1 (ko) | 2014-11-13 |
Family
ID=52453112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/004012 WO2014182044A1 (ko) | 2013-05-06 | 2014-05-07 | 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10111856B2 (ko) |
EP (1) | EP2995304B1 (ko) |
JP (1) | JP2016526019A (ko) |
KR (1) | KR102200014B1 (ko) |
CN (1) | CN105473137B (ko) |
HK (1) | HK1217285A1 (ko) |
WO (1) | WO2014182044A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114848702A (zh) * | 2015-10-30 | 2022-08-05 | 株式会社Hubio | 含有香豆雌酚的发芽发酵豆提取物及包含其的组合物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170002846A (ko) | 2015-06-30 | 2017-01-09 | (주)아모레퍼시픽 | 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물 |
KR101749967B1 (ko) * | 2015-11-09 | 2017-06-23 | 대한민국 | 콩 발아배아 추출물을 포함하는 비만의 예방 또는 치료용 약학 조성물 |
KR20180036167A (ko) * | 2016-09-30 | 2018-04-09 | (주)아모레퍼시픽 | 풋귤수로 처리한 발아콩 유래의 두즙 펩타이드를 포함하는 근력 및 근육량 향상용 조성물 |
KR102226151B1 (ko) * | 2017-11-20 | 2021-03-11 | (주)아모레퍼시픽 | 콩과식물 배양근을 이용한 쿠메스트롤 생산 방법 |
KR20200040583A (ko) * | 2018-10-10 | 2020-04-20 | (주)아모레퍼시픽 | 코티존 환원효소 저해용 조성물 |
CN109589404A (zh) * | 2018-11-27 | 2019-04-09 | 杭州元研细胞生物科技有限公司 | 一种用于女性生殖系统抗衰修复产品及其制备方法 |
KR102362968B1 (ko) | 2019-11-25 | 2022-02-17 | 주식회사 쎌바이오텍 | 유산균 및 프리바이오틱스를 포함하는 갱년기 증상의 예방, 완화 또는 치료용 조성물 |
WO2023140407A1 (ko) * | 2022-01-21 | 2023-07-27 | 경상국립대학교병원 | 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
WO2023229356A2 (ko) * | 2022-05-25 | 2023-11-30 | 천현수 | 콩 및 상추 발효물의 혼합물을 유효성분으로 포함하는 여성 갱년기 증상의 예방, 개선 또는 치료용 조성물 |
KR20240011288A (ko) | 2022-07-18 | 2024-01-26 | 전남대학교산학협력단 | 에스트로겐 분비저하에 의한 여성 갱년기 장애 개선용 조성물 및 그의 제조방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020000980A (ko) * | 2000-06-23 | 2002-01-09 | 임병철 | 페룰산에스테르 유도체, 3,9-디페룰릴쿠메스트롤 및 이를함유한 화장료 |
KR20110089107A (ko) * | 2010-01-29 | 2011-08-04 | (주)아모레퍼시픽 | 쿠메스트롤 생산 방법 및 그에 의해 생산된 쿠메스트롤 |
KR20110110052A (ko) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 |
KR20110110053A (ko) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물 |
WO2012006750A1 (en) * | 2010-07-12 | 2012-01-19 | Frutarom Switzerland Ltd. | Nutraceutical composition obtained from fungus-challenged soy seedlings |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001272028A1 (en) | 2000-06-26 | 2002-01-08 | The Regents Of The University Of Michigan | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
FR2814950B1 (fr) * | 2000-10-05 | 2003-08-08 | Oreal | Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement |
JP2004067590A (ja) | 2002-08-06 | 2004-03-04 | Naris Cosmetics Co Ltd | 女性ホルモン産生促進剤及びこれを含有する皮膚外用剤 |
CN1475227A (zh) * | 2002-08-16 | 2004-02-18 | 刘佳明 | 防治绝经期综合症、骨质疏松症和乳腺癌的组合物 |
FR2863886B1 (fr) | 2003-12-22 | 2007-05-04 | Oreal | Utilisation d'un ligand steroidien ou non-steroidien du recepteur ecr dans une preparation cosmetique ou dermatologique pour maintenir l'homeostasie cutanee. |
JP2006189675A (ja) | 2005-01-07 | 2006-07-20 | Canon Inc | 現像剤補給容器 |
KR100706279B1 (ko) | 2005-11-11 | 2007-04-12 | (주)아모레퍼시픽 | 쿠메스트롤을 함유한 비만 개선 및 예방용 조성물 |
GB2474522B (en) * | 2009-10-19 | 2014-09-03 | Advanced Risc Mach Ltd | Register state saving and restoring |
WO2011122879A2 (ko) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물 |
-
2014
- 2014-05-02 KR KR1020140053471A patent/KR102200014B1/ko active IP Right Review Request
- 2014-05-07 JP JP2016512830A patent/JP2016526019A/ja active Pending
- 2014-05-07 CN CN201480031291.9A patent/CN105473137B/zh active Active
- 2014-05-07 WO PCT/KR2014/004012 patent/WO2014182044A1/ko active Application Filing
- 2014-05-07 EP EP14794096.9A patent/EP2995304B1/en active Active
- 2014-05-07 US US14/888,623 patent/US10111856B2/en active Active
-
2016
- 2016-05-03 HK HK16105025.0A patent/HK1217285A1/zh unknown
-
2018
- 2018-05-25 US US15/989,544 patent/US10959981B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020000980A (ko) * | 2000-06-23 | 2002-01-09 | 임병철 | 페룰산에스테르 유도체, 3,9-디페룰릴쿠메스트롤 및 이를함유한 화장료 |
KR20110089107A (ko) * | 2010-01-29 | 2011-08-04 | (주)아모레퍼시픽 | 쿠메스트롤 생산 방법 및 그에 의해 생산된 쿠메스트롤 |
KR20110110052A (ko) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 |
KR20110110053A (ko) * | 2010-03-31 | 2011-10-06 | (주)아모레퍼시픽 | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물 |
WO2012006750A1 (en) * | 2010-07-12 | 2012-01-19 | Frutarom Switzerland Ltd. | Nutraceutical composition obtained from fungus-challenged soy seedlings |
Non-Patent Citations (1)
Title |
---|
See also references of EP2995304A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114848702A (zh) * | 2015-10-30 | 2022-08-05 | 株式会社Hubio | 含有香豆雌酚的发芽发酵豆提取物及包含其的组合物 |
Also Published As
Publication number | Publication date |
---|---|
US10959981B2 (en) | 2021-03-30 |
CN105473137A (zh) | 2016-04-06 |
US10111856B2 (en) | 2018-10-30 |
US20180271830A1 (en) | 2018-09-27 |
EP2995304B1 (en) | 2022-01-19 |
KR20140131881A (ko) | 2014-11-14 |
CN105473137B (zh) | 2018-08-21 |
EP2995304A4 (en) | 2017-01-25 |
KR102200014B9 (ko) | 2022-03-23 |
US20160089359A1 (en) | 2016-03-31 |
HK1217285A1 (zh) | 2017-01-06 |
KR102200014B1 (ko) | 2021-01-08 |
JP2016526019A (ja) | 2016-09-01 |
EP2995304A1 (en) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014182044A1 (ko) | 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물 | |
WO2016047907A1 (ko) | 틴달화 유산균 사균체를 유효성분으로 포함하는 피부 보습 또는 주름개선용 조성물 | |
WO2020060060A1 (ko) | 병풀 부정근 추출물을 유효성분으로 함유하는 피부 미백 및 주름개선용 화장료 조성물 | |
WO2018174453A1 (ko) | 엉겅퀴 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물 | |
WO2017222317A1 (ko) | 이오논 또는 이의 염을 유효성분으로 함유하는 피부보습 개선, 피부각질 제거, 피부탄력 증진, 홍반 억제, 피부주름 개선 또는 피부광노화 개선 효과를 갖는 조성물 | |
KR20200063855A (ko) | 밀크씨슬 꽃 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물 | |
WO2019143055A1 (ko) | 아스페르길루스 크리스타투스 균주로 발효시킨 발효 콩의 추출물을 포함하는 피부미용 개선용 조성물 | |
KR101088069B1 (ko) | 판두라틴 유도체 또는 이를 함유하는 카엠페리아 판두라타 추출물의 신규한 용도 | |
WO2017213346A1 (ko) | 디오스민 또는 이의 염을 유효성분으로 함유하는 피부보습 개선, 피부각질 제거, 피부탄력 증진, 홍반 억제, 피부주름 개선 또는 피부광노화 개선 효과를 갖는 조성물 | |
WO2018004141A1 (ko) | 시멘, 베헨산, 2-메톡시나프탈렌, 티몰 및 이들의 염으로 이루어진 군에서 선택된 어느 하나 이상을 유효성분으로 함유하는 피부보습 개선, 피부각질 제거, 피부탄력 증진, 홍반 억제, 피부주름 개선 또는 피부광노화 개선 효과를 갖는 조성물 | |
WO2021080129A1 (ko) | 하이드란제놀 또는 필로둘신을 유효성분으로 하는 피부장벽 강화 및 아토피 피부염 개선용 조성물 | |
WO2020256381A1 (ko) | 옥타데센 또는 이의 염을 유효성분으로 포함하는 피부 미백용 조성물 | |
WO2016003120A1 (ko) | 알피나 골무꽃 추출물을 포함하는 미백용 조성물 | |
WO2020256380A1 (ko) | 카르본 또는 이의 염을 유효성분으로 포함하는 피부 미백용 조성물 | |
WO2021080298A1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2015167240A1 (ko) | 알피나 골무꽃 추출물을 포함하는 조성물 | |
WO2016117762A1 (ko) | 구스베리 추출물 또는 글루타티온을 포함하는 조성물 | |
KR101579500B1 (ko) | 율무뿌리 추출물을 포함하는 미백용 조성물 | |
WO2015152653A1 (ko) | 알파인 웜우드 추출물을 포함하는 조성물 | |
KR20160068316A (ko) | 황벽 추출물을 포함하는 미백용 조성물 | |
WO2015152552A1 (ko) | 알파인 웜우드 추출물을 포함하는 조성물 | |
US20220193163A1 (en) | Composition comprising actinidia polygama extract for alleviating skin damage or moisturizing skin | |
WO2015167239A1 (ko) | 산형화 추출물을 포함하는 조성물 | |
KR102524917B1 (ko) | 택란 추출물을 유효성분으로 함유하는 피부미백용 조성물 및 이의 제조방법 | |
WO2017204383A1 (ko) | 밀배아 추출물을 포함하는 여성암 억제 및 치료용 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480031291.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14794096 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14888623 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016512830 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014794096 Country of ref document: EP |